Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-finding study of ABL001 alone and in combination with TKIs in Ph+ CML and Ph+ ALL
jRCT2080222881Phase 1Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of tovecimig in chronic myelogenous leukemia (CML), chronic myeloid leukemia blast phase (CML-BP) and acute lymphoblastic leukemia (ALL) (4 arms), sponsored by Novartis. Primary endpoints: Maximum tolerated dose and recommended dose of ABL001 (alone and in combination) and Safety and tolerability of ABL001 (alone and in combination). Started Jun 2015; status: completed.
02
Drugs
tovecimig
03
Conditions
chronic myelogenous leukemia (CML)chronic myeloid leukemia blast phase (CML-BP)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2080222881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222881.